Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELOX Stock Price Chart Interactive Chart >
ELOX Price/Volume Stats
| Current price | $3.31 | 52-week high | $24.60 |
| Prev. close | $3.16 | 52-week low | $1.70 |
| Day low | $3.13 | Volume | 13,300 |
| Day high | $3.44 | Avg. volume | 142,631 |
| 50-day MA | $3.77 | Dividend yield | N/A |
| 200-day MA | $7.42 | Market Cap | 7.17M |
Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.
Latest ELOX News From Around the Web
Below are the latest news stories about ELOXX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELOX as an investment opportunity.
Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceWATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 12:00 PM ET. A live webcast of the presentation and a replay of the presentation will be available on the Company’s website at https://investors.eloxxpharma.com/events-presentations. About Eloxx Pharmaceuticals Eloxx |
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient DosedTopline results expected in first half of 2023WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Topline results are expected in the first half of 2023. “Patients with Alport syndrome with nonsense mutations lack disea |
Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidateEloxx Pharmaceuticals president and CEO Sumit Aggarwal joins Proactive's Natalie Stoberman to discuss the latest update on the clinical study for its lead investigational product candidate ELX-02. |
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport SyndromeTopline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. “With enrollment of the first patients in our Phase 2 study of ELX-0 |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayThe final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! |
ELOX Price Returns
| 1-mo | N/A |
| 3-mo | 55.40% |
| 6-mo | -51.24% |
| 1-year | -82.01% |
| 3-year | -96.72% |
| 5-year | -99.08% |
| YTD | 81.87% |
| 2022 | -93.56% |
| 2021 | -82.26% |
| 2020 | -45.92% |
| 2019 | -38.72% |
| 2018 | 50.13% |
Loading social stream, please wait...